AstraZeneca’s (AZN) “Hold” Rating Reiterated at Shore Capital

Share on StockTwits

Shore Capital reiterated their hold rating on shares of AstraZeneca (LON:AZN) in a research note issued to investors on Tuesday morning.

A number of other research firms have also recently issued reports on AZN. Barclays reissued an overweight rating and issued a GBX 6,600 ($86.24) price target (up previously from GBX 6,500 ($84.93)) on shares of AstraZeneca in a research note on Friday, August 10th. HSBC set a GBX 4,840 ($63.24) price target on shares of AstraZeneca and gave the company a sell rating in a research note on Wednesday, August 15th. Credit Suisse Group reissued an outperform rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Liberum Capital reissued a hold rating on shares of AstraZeneca in a research note on Tuesday, October 23rd. Finally, JPMorgan Chase & Co. reissued an overweight rating and issued a GBX 6,500 ($84.93) price target on shares of AstraZeneca in a research note on Tuesday, August 21st. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and eleven have assigned a buy rating to the stock. AstraZeneca has an average rating of Hold and an average price target of GBX 5,804.11 ($75.84).

AstraZeneca stock opened at GBX 6,106.74 ($79.80) on Tuesday. AstraZeneca has a 1 year low of GBX 4,260 ($55.66) and a 1 year high of GBX 5,520 ($72.13).

About AstraZeneca

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Read More: What is dollar cost averaging (DCA)?

Analyst Recommendations for AstraZeneca (LON:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply